Australia markets open in 1 hour 5 minutes

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
135.29-0.16 (-0.12%)
At close: 04:00PM EDT
135.29 0.00 (0.00%)
After hours: 04:42PM EDT

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
https://www.neurocrine.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees1,448

Key executives

NameTitlePayExercisedYear born
Dr. Kevin C. Gorman Ph.D.CEO & Director2.05MN/A1958
Mr. Matthew C. AbernethyChief Financial Officer1.06MN/A1980
Dr. Jude Onyia Ph.D.Chief Scientific Officer1.22MN/A1964
Mr. Kyle W. Gano Ph.D.Chief Business Development & Strategy Officer990.12kN/A1973
Dr. Eiry Wyn Roberts M.D.Chief Medical Officer1.12M4.15M1964
Jane SorensenHead of Investor RelationsN/AN/AN/A
Mr. Darin M. Lippoldt Esq.Chief Legal Officer & Corporate Secretary921.01k2.98M1966
Ms. Julie S. CookeChief Human Resources OfficerN/AN/A1966
Mr. Eric S. BenevichChief Commercial Officer805k295.52k1965
Mr. David Warren BoyerChief Corporate Affairs OfficerN/AN/A1980
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Corporate governance

Neurocrine Biosciences, Inc.’s ISS governance QualityScore as of 1 June 2024 is 2. The pillar scores are Audit: 6; Board: 1; Shareholder rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.